Based in Canada, Ability is a startup.
Ability develops precision biotherapeutic antibodies using its proprietary AI-driven discovery platform AbiLeap™ to create novel immune cell-targeting therapies for autoimmune, inflammatory diseases, and cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.